Venetoclax Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Venetoclax Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
880
Registered trials
1407
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Venetoclax can convert its Small molecule drug profile and Bcl-2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Venetoclax (query alias: Venetoclax) |
|---|---|
| Modality / target | Small molecule drug; Bcl-2; Bcl-2 inhibitors |
| Highest global status | Approved |
| Originator | Genentech, Inc., AbbVie, Inc. |
| Active developers | Syndax Pharmaceuticals, Inc., AbbVie LLC, Acerta Pharma BV |
The MCP disease footprint includes Mantle cell lymphoma recurrent, Mantle cell lymphoma refractory, Chronic lymphocytic leukaemia refractory. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07672262 | Phase 2 | Recruiting | 226 | Leukemia-Free Survival (LFS) |
| NCT07690891 | Phase 2 | Not yet recruiting | 30 | Undetectable MRD |
| NCT07679334 | Phase 1 | Not yet recruiting | 20 | To determine the maximum tolerated dose (MTD) of the treatment regimen. |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A phase 1 study of R-GDP–venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18)
Phase 1; n=24; evaluation: Positive. Reported fields: AE = The main adverse events were hematologic symptoms, infection, gastrointestinal symptoms, and fatigue. Rates of febrile neutropenia improved after an amendment introducing mandatory granulocyte colony-stimulating factor.
Venetoclax Plus Dose-adjusted R-EPOCH or R-CHOP for Richter's Syndrome
Phase 2; n=69; evaluation: not stated. Reported fields: 3-month Rate of Complete Response (CR) = 0.286 proportion of participants (95% Confidence Interval, 0.16 - 0.448); 3-month Rate of Complete Response (CR) = 0.65 proportion of participants (95% Confidence Interval, 0.41 - 0.85); -
Safety and Efficacy of Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients (Aged 18-59) With Acute Myeloid Leukemia
Phase 2; n=36; evaluation: not stated. Reported fields: Response Rate, Measured by the European Leukemia Net Definition: (CRMRD-+CR+CRi+MLFS) = 25 Participants ; -; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Venetoclax addresses Mantle cell lymphoma recurrent, Mantle cell lymphoma refractory, Chronic lymphocytic leukaemia refractory. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2021-12-13 | MD Anderson Cancer Center will assess the combined effectiveness of Kura's KO-539 and venetoclax in AML models. | Phase 2 | Financial terms not disclosed |
| 2020-09-03 | AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy | Phase 2 | US$200.0M upfront; US$840.0M milestones; US$1,040.0M stated total |
| 2018-08-17 | Tolero Pharmaceuticals Announces Clinical Research Collaboration with AbbVie for Acute Myeloid Leukemia Trial | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Compositions comprising an Anti-mir-126 nucleic acid and BCL-2 homology 3 (BH3) mimetic and methods of use”. The milestone feed surfaced a patent-application signal described as “Process for preparing venetoclax, and method for preparing an amorphous form of venetoclax”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
